PPC
APLS

Park Place Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Park Place Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-23
Closed -$663 – 813
2024
Q3 		$663 Hold
23
– – ﹤0.01% 842
2024
Q2 		$882 Hold
23
– – ﹤0.01% 834
2024
Q1 		$1.35K Hold
23
– – ﹤0.01% 867
2023
Q4 		$1.38K Hold
23
– – ﹤0.01% 817
2023
Q3 		$875 Hold
23
– – ﹤0.01% 984
2023
Q2 		$2.1K Hold
23
– – ﹤0.01% 940
2023
Q1 		$1.52K Buy
+23
New +$1.33K ﹤0.01% 974

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Park Place Capital's APLS Position: Q4 2024 in Review

Park Place Capital sold out of Apellis Pharmaceuticals (APLS) in Q4 2024, closing a stake of 23 shares — an estimated $663 sold.

Park Place Capital first reported a position in APLS in Q1 2023 and held it in 7 quarters. The position peaked at $2.1K in Q2 2023. 260 funds tracked by Wall St. Rank hold APLS as of Q4 2024.

  • Park Place Capital reported no remaining Apellis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Park Place Capital sold 23 Apellis Pharmaceuticals shares in Q4 2024, an estimated $663.
  • Park Place Capital first reported a position in Apellis Pharmaceuticals in Q1 2023 and held it in 7 quarters.
  • Park Place Capital's Apellis Pharmaceuticals position peaked at $2.1K in Q2 2023.
  • 260 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2024.

Based on Park Place Capital's 13F filing for Q4 2024, filed 17 Jan 2025.